Zealand Pharma A/S
Zealand Pharma is a biotech company that develops peptide-based medicines for gastrointestinal, metabolic, and other diseases. They offer Dasiglucagon for severe hypoglycemia treatment and are developing it further for congenital hyperinsulinism. Their pipeline also includes glepaglutide for short bowel syndrome.
Overview
Strengths
- Price to book ratio (2.87) is lower than the sector mean (24.44).
Weaknesses
- With a depreciation Potential of -100.00%, based on our fundamental analysis, it suggests the stock may be overvalued.
- Analysts expect revenues to decline in the coming year.
- The company have lower returns than the sector in which it operates. ROIC (0.00%) is significantly lower than the sector mean (6.02%).
- EBITDA Margin (0.00%) appears relatively low.
Key Financial Data
| Indicator | Value |
|---|
| PER | 100.0 |
| EV/EBITDA | 100.0 |
| Price/Free Cash Flow' | 100.0 |
| ROIC | -% |
| Net Debt/EBITDA | 0.1 |